Meridian Bioscience, Inc.
VIVO · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.80 | 0.23 | 0.18 | 9.35 |
| FCF Yield | 5.31% | 5.73% | 6.09% | 7.87% |
| EV / EBITDA | 18.57 | 8.02 | 9.94 | 9.68 |
| Quality | ||||
| ROIC | 10.66% | 18.15% | 13.47% | 8.30% |
| Gross Margin | 56.56% | 63.27% | 61.60% | 58.86% |
| Cash Conversion Ratio | 1.94 | 0.94 | 1.04 | 1.47 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.50% | 16.51% | 5.90% | 0.04% |
| Free Cash Flow Growth | 51.89% | 8.68% | 39.47% | 4.75% |
| Safety | ||||
| Net Debt / EBITDA | -0.70 | 0.15 | 0.23 | 0.31 |
| Interest Coverage | 46.68 | 49.54 | 23.30 | 16.81 |
| Efficiency | ||||
| Inventory Turnover | 2.13 | 1.52 | 1.59 | 2.09 |
| Cash Conversion Cycle | 178.07 | 265.16 | 240.11 | 207.58 |